Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Matthew Harlin, Craig Chepke, Frank Larsen, Karimah S Bell Lynum, Sanjeda R Chumki, Heather Fitzgerald, Pedro Such, Jessica Madera-McDonough, Murat Yildirim, Moeen Panni & Stephen R Saklad. (2023) Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison. Neuropsychiatric Disease and Treatment 19, pages 1409-1416.
Read now
Read now
Rahul Dhanda, Della Varghese, Vijay R Nadipelli, Maurizio Fava, Namita Joshi, Caitlyn T Solem, James A Graham, Susan M Learned & Christian Heidbreder. (2019) Patient-reported outcomes in schizophrenia patients treated with once-monthly extended-release risperidone in a long-term clinical study. Patient Preference and Adherence 13, pages 1037-1050.
Read now
Read now
Leslie Citrome. (2012) Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability. Expert Opinion on Drug Metabolism & Toxicology 8:7, pages 873-888.
Read now
Read now
Leslie Citrome. (2010) Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opinion on Drug Metabolism & Toxicology 6:12, pages 1551-1564.
Read now
Read now
Articles from other publishers (11)
Leslie Citrome. (2021) Long-acting injectable antipsychotics: what, when, and how. CNS Spectrums 26:2, pages 118-129.
Crossref
Crossref
Dominique Vodovar, Isabelle Malissin, Nicolas Deye, Frédéric J. Baud & Bruno Mégarbane. (2014) Olanzapine Postinjection Delirium/Sedation Syndrome: An Unrecognized Diagnosis in the Emergency Department. The Journal of Emergency Medicine 47:1, pages e23-e24.
Crossref
Crossref
Malcolm Mitchell, Prajakti Kothare, Richard Bergstrom, Fangyi Zhao, Kai Yu Jen, Daniel Walker, Jason Johnson & David McDonnell. (2013) Single- and Multiple-Dose Pharmacokinetic, Safety, and Tolerability Profiles of Olanzapine Long-Acting Injection: An Open-Label, Multicenter, Nonrandomized Study in Patients With Schizophrenia. Clinical Therapeutics 35:12, pages 1890-1908.
Crossref
Crossref
Leslie CitromeLeslie Citrome. 2013. Handbook of Treatment-resistant Schizophrenia. Handbook of Treatment-resistant Schizophrenia
20
28
.
Ricardo Millán-González. (2012) Consentimientos informados y aprobación por parte de los comités de ética en los estudios de antipsicóticos atípicos para el manejo del delírium. Revista Colombiana de Psiquiatría 41:1, pages 150-164.
Crossref
Crossref
Jamie D. Croxtall. (2012) Aripiprazole. CNS Drugs 26:2, pages 155-183.
Crossref
Crossref
H. Ascher-Svanum, X. Peng, W. Montgomery, D.E. Faries, A.H. Lawson, M.M. Witte, D. Novick, N. Jemiai, E. Perrin & D.P. McDonnell. (2020) Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia. European Psychiatry 26:5, pages 313-319.
Crossref
Crossref
Heidi J. WehringSheryl ThedfordMaju KoolaDeanna L. Kelly. (2011) Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection. Journal of Central Nervous System Disease 3, pages JCNSD.S4091.
Crossref
Crossref
S. Kasper & H.-J. Möller. 2011. Psychiatrie, Psychosomatik, Psychotherapie. Psychiatrie, Psychosomatik, Psychotherapie
731
766
.
James E. Frampton. (2010) Olanzapine Long-Acting Injection. Drugs 70:17, pages 2289-2313.
Crossref
Crossref
Adamo Fini, Cristina Cavallari, Giancarlo Ceschel & Antonio M. Rabasco. (2010) Bimodal Release of Olanzapine from Lipid Microspheres. Journal of Pharmaceutical Sciences 99:10, pages 4251-4260.
Crossref
Crossref